The role of ADC values within the normal-appearing brain in the prognosis of multiple sclerosis activity during interferon-β therapy in the 3-year follow-up: a preliminary report

Anna Zacharzewska-Gondek1, Anna Pokryszko-Dragan2, Sławomir Budrewicz2, Marek Sąsiadek3, Grzegorz Trybek3 & Joanna Bladowska1

Predictors of multiple sclerosis (MS) activity during disease-modifying treatment are being extensively investigated. The aim of this study was to assess the prognosis of NEDA (no evidence of disease activity) status during IFN-β (interferon-β) treatment, using apparent diffusion coefficient (ADC) measurements obtained at initial MRI (magnetic resonance imaging). In 87 MS patients treated with IFN-β, ADC values were calculated for 13 regions of normal-appearing white and grey matter (NAWM, NAGM) based on MRI performed with a 1.5 T magnet before (MS0, n = 45) or after one year of therapy (MS1, n = 42). Associations were evaluated between ADC, conventional MRI findings, demographic and clinical factors and NEDA status within the following 3 years using logistic, Cox and multinomial logistic regression models. NEDA rates in the MS0 group were 64.4%, 46.5% and 33.3% after the 1st, 2nd and 3rd year of treatment, respectively and in MS1 patients 71.4% and 48.7% for the periods 1st–2nd and 1st–3rd years of treatment, respectively. ADC values in the NAWM regions contributed to loss of NEDA and its clinical and radiological components, with a 1–3% increase in the risk of NEDA loss (p = 0.0001–0.0489) in both groups. ADC measurements may have an additional prognostic value with regard to NEDA status.

Multiple sclerosis (MS) is an inflammatory disease causing multifocal demyelination and axonopathy within the brain. Immunomodulatory therapy is applied to reduce activity and to delay the progression of this disease. The course of MS, natural and modified by treatment, shows substantial variability and it is crucial to identify the subjects with active disease and poor response to treatment at an early stage, in order to optimise the therapeutic strategy. To date, variable demographic and clinical factors and conventional radiological measures were investigated as potential predictors of the course of MS with mixed results, thus searching for reliable biomarkers in this field is still needed. Recently, advanced neuro-imaging techniques allowing for a deeper insight into the pathology of MS have attracted more attention in the context of prediction of disease activity or disability progression during immunomodulatory treatment.

Response to treatment has traditionally been evaluated based on clinical (relapse rate, disability progression) and radiological (presence of demyelinating plaques in MRI—magnetic resonance imaging) aspects. These

1Department of General and Interventional Radiology and Neuroradiology, Wrocław Medical University, 213 Borowska Street, 50-556 Wrocław, Poland. 2Department and Clinic of Neurology, Wrocław Medical University, 213 Borowska Street, 50-556 Wrocław, Poland. 3Department of Oral Surgery, Pomeranian Medical University, 72 Powstańców Wielkopolskich Street, 70-111 Szczecin, Poland. 4email: aniazacha@gazeta.pl
were quantified using composite scores, including i.a. Rio score, modified Rio score and MAGNIMS score.

Diffusion-weighted imaging (DWI) is a nonconventional imaging method based on random movements of water molecules in extracellular space. Diffusion may be measured using i.a. a mathematically calculated apparent diffusion coefficient (ADC), which detects changes in the overall diffusion irrespective of the motion direction. Even subtle impairment of tissue architecture may result in facilitated diffusion, which is detectable as increased ADC or mean diffusivity (MD) values, as well as decreased fractional anisotropy (FA) values. Diffusion may be measured using i.a. a mathematically calculated apparent diffusion coefficient (ADC), which detects changes in the overall diffusion irrespective of the motion direction. Even subtle impairment of tissue architecture may result in facilitated diffusion, which is detectable as increased ADC or mean diffusivity (MD) values, as well as decreased fractional anisotropy (FA) values. It was reported in a radiologic-histopathologic study that facilitated diffusion in normal-appearing white and grey matter (NAWM, NAGM) beyond demyelinating plaques in MS patients is related to neurodegeneration, and such changes are missed on conventional MR images.

Methods

Study design. This was a retrospective, single-centre, independent, observational study approved by the Ethics Committee of Wroclaw Medical University, Poland (decision number 766/2017) and was conducted in accordance with the Helsinki Declaration. Each patient gave their informed and signed consent before participation in the MR examination.

Group characteristics. There were 236 patients with MS studied in the Department of Radiology between 2008 and 2017.

Finally, the study comprised 87 patients (28 men, 59 women, aged 33.5 years at the beginning of treatment) with MS, who fulfilled the following inclusion criteria:

1. Patients with clinically defined relapsing–remitting course of MS, according to the 2010 revision of McDonald’s criteria;
2. IFN-β as the only immunomodulatory treatment applied;
3. Availability of brain MRI examinations with appropriate DWI sequence performed before or after 1 year of treatment with IFN-β in the tertiary referral centre;
4. Up to 45 cerebral hyperintense T2/FLAIR lesions visible on conventional MRI;
5. No visible changes on conventional MRI lesions within the white and grey matter within regions of interest for ADC measurements.

All MS patients who did not fulfil the criteria mentioned above were excluded, which is depicted in the flow-chart (Fig. 1).

The patients were divided into two groups according to the timing of the initial MRI:

- MS0 group (n = 45)—1st MRI before starting treatment = true baseline MRI;
- MS1 group (n = 42)—1st MRI after 1 year of treatment with IFN-β and no available previous MRI scans = on-treatment MRI as baseline.

Demographic, clinical and conventional MRI characteristics of the sample are shown in detail in Table 1. Patients were treated with 3 available types of IFN-β—IFN-β-1a i.m. (Avonex), IFN-β-1b s.c. (Betaferon) and IFN-β-1a s.c. (Rebif). Medication was continued within the 1st year of follow-up without change of treatment in all patients. Between the 1st and 3rd year of follow-up treatment was switched due to clinical and/or MRI disease activity in 17.8% (n = 8) of MS0 patients [to fingolimod (n = 3), glatiramer acetate (n = 3) and dimethyl fumarate (n = 2)]. In the MS1 group none of the patients had their treatment switched during follow-up.

NEDA definition and study outcomes. The main endpoints of our study was a NEDA failure, which was assessed after each year of IFN-β treatment in the MS0 group and within 1st–2nd and 1st–3rd year intervals for the MS1 group. In our study NEDA was defined as having no clinical relapses and/or no disability progression (“clinical” NEDA) and no new/enlarging or no gadolinium enhancing lesion(s) (“MRI” NEDA). A relapse was denoted as a monophasic (sub)acute clinical episode with symptoms and signs of neurological deficit, with a duration of at least 24 h, with or without recovery, and in the absence of fever or infection. Since progression of the disability was observed only temporarily during relapses and in none of the patients sustained disability beyond relapses was noted, these clinical aspects of NEDA were not rated separately. New and enlarged lesion(s) were assessed on T2/FLAIR and T1 post-contrast sequence. The beginning of treatment with IFN-β was a start point for evaluation NEDA in the MS0 group with 1st MRI before therapy. In the MS1 group with 1st MRI after 1 year of treatment none of the patients had a relapse in the 1st year of treatment but history of new lesions formation was unknown in this period, which precluded us from using NEDA from the beginning of...
treatment—consequently in this group the start point for NEDA assessment was set at the 1st MRI. Three-years follow-up means that patients in both groups were clinically observed from the beginning of IFN-β treatment until 3 years had passed. However, because of different time points for starting NEDA assessment, the total length of MRI follow-up was at least 3 years for the MS0 group and 2 years for the MS1 group (from the 1st MRI after 1 year of treatment to finishing the 3-year follow-up procedure). Majority of the patients were assessed clinically and radiologically at least every 12 months from the onset of treatment until finishing the 3-year follow-up, unless a few of them omitted the last MRI control scan.

Endpoints for the MS0 group with 1st MRI before treatment are provided first and analogous endpoints for the MS1 group are depicted in round brackets, with subdivisions according to the statistical model used:

**Model 1:**
- loss of NEDA within the 1st year of treatment (not applicable for the MS1 group),
- loss of NEDA within the 2nd year of treatment (between the 1st and 2nd years of treatment),
- loss of NEDA within the 3rd year of treatment (between the 1st and 3rd years of treatment),
- loss of “MRI” NEDA within the 1st year of treatment (not applicable for the MS1 group),
- loss of “MRI” NEDA within the 2nd year of treatment (between the 1st and 2nd years of treatment),
- loss of “MRI” NEDA within the 3rd year of treatment (between the 1st and 3rd years of treatment),
- loss of “clinical” NEDA within the 1st year of treatment (not applicable for the MS1 group),
- loss of “clinical” NEDA within the 2nd year of treatment (between the 1st and 2nd years of treatment),
- loss of “clinical” NEDA within the 3rd year of treatment (between the 1st and 3rd years of treatment),
- treatment of IFN-β shorter than 3 years (the same),
- alternative treatment within 3 years of follow-up (not applicable for the MS1 group);

**Model 2:**
- time to loss of NEDA within 3 years of treatment (from the 1st MRI to 3 years of treatment),
- time to loss of “MRI” NEDA within 3 years of treatment (from the 1st MRI to 3 years of treatment),
- time to loss of “clinical” NEDA within 3 years of treatment (from the 1st MRI to 3 years of treatment),
- time to IFN-β treatment shorter than 3 years (the same),
- time to alternative treatment in 3 years of follow-up (not applicable for the MS1 group);

**Model 3:**
- reasons for loss of NEDA (the same).

**Potential prognostic factors of loss of NEDA and other related endpoints during IFN-β treatment.** Demographic and clinical factors evaluated as potential prognostic indicators of all aforementioned endpoints during IFN-β treatment were as follows: sex, age at onset of the disease, age at the beginning of treatment, age at the 1st MRI, disease duration until the 1st MRI and onset of treatment and baseline EDSS. Investigated potential conventional and advanced radiological prognostic factors included:
| Demographic, clinical and radiological characteristics | MS0 group—the 1st MRI before treatment with IFN-β | MS1 group—the 1st MRI after 1 year of treatment with IFN-β | on-treatment MRI as baseline |
|-------------------------------------------------------|---------------------------------|---------------------------------|-------------------------|
| The total number of analysed patients                  | 45                              | 42                              | 42                      |
| Female:Male (% of female)                              | 33:12 (73.3%)                  | 26:16 (61.9%)                   | 1.63:1                  |
| Ratio                                                 | 2.75:1                          |                                 |                         |
| **Patients treated with [n of patients (%)]**          |                                 |                                 |                         |
| Avonex                                                | 9 (20%)                         | 8 (19%)                         |                         |
| Betaferon                                             | 25 (55.6%)                      | 27 (64.3%)                      |                         |
| Rebif                                                 | 11 (24.4%)                      | 7 (16.7%)                       |                         |
| Mean age at the onset of the disease in years ± SD (range) | 32.5 ± 11.3 (18–58)            | 28.0 ± 7.9 (13–52)             |                         |
| Mean age at the 1st MRI in years ± SD (range)          | 35.0 ± 11.7 (19–61)             | 32.7 ± 7.8 (19–56)             |                         |
| Mean age at the beginning of treatment in years ± SD (range) | 35.2 ± 11.6 (19–61)            | 31.7 ± 7.8 (18–55)             |                         |
| Mean time of the disease duration from the onset to treatment beginning in months ± SD (range) | 35.7 ± 38.9 (2–156)            | 48.9 ± 42.5 (2–192)            |                         |
| Mean time of the disease duration from the onset to the 1st MRI in months ± SD (range) | 32.1 ± 38.4 (1–144)            | 60.9 ± 42.5 (14–204)           |                         |
| Mean baseline EDSS ± SD                                | 2.3 ± 1.3                       | 2.0 ± 0.8                       |                         |
| Median baseline EDSS (range)                           | 2.0 (1–7)                       | 2.0 (1–5)                       |                         |
| Mean T2/FLAIR lesion number at the 1st MRI ± SD (range) | 20.5 ± 12.9 (1–45)             | 19.3 ± 10.4 (3–45)             |                         |
| Presence of Gd-enhancing lesions at the 1st MRI—[n of patients (% of patients with contrast administration)] | 43 (95.6%)                      | 36 (85.7%)                      |                         |
| Presence of cervical spinal cord lesion at the 1st MRI—[n of patients (%)] | 0.7 ± 2.0 (1–11)               | 0.1 ± 0.3 (1–1)                |                         |
| Mean time to loss of NEDA form the treatment beginning in the 3-years FU in month ± SD (range) | 16.2 ± 8.4 (3–35)              | NA                             |                         |
| Mean time to loss of NEDA from the 1st MR in the 2-years FU in months ± SD (range) | NA                              | 13.7 ± 4.4 (8–24)              |                         |
| Mean time to new lesion(s) formation from the treatment beginning in the 3-year FU (loss of "MRI" NEDA) in months ± SD (range) | 18.5 ± 7.8 (8–36)              | NA                             |                         |
| Mean time to new lesion(s) formation from the 1st MRI in the 2-years FU (loss of "MRI" NEDA) in months ± SD (range) | NA                              | 13.7 ± 3.8 (11–23)             |                         |
| Mean time to relapse from the treatment beginning in the 3-years FU (loss of "clinical" NEDA) in months ± SD (range) | 13.7 ± 7.8 (3–25)              | NA                             |                         |
| Mean time to relapse from the 1st MRI in the 2-years FU (loss of "clinical" NEDA) in months ± SD (range) | NA                              | 14.7 ± 6.2 (8–24)              |                         |
| Patients, who discontinued IFN-β treatment in the 3-year FU [n (%)] | 9 (20%)                         | 1 (2.4%)                        |                         |
| Mean time of IFN-β treatment in the 3-years FU ± SD (range) | 33.6 ± 5.4 (12–36)             | 35.8 ± 1.4 (27–36)             |                         |
| Patients, who switched treatment option in the 3-year FU [n (%)] | 8 (17.8%)                       | 0 (0%)                          |                         |
| Mean time to alternative therapy in months ± SD (range) | 23.5 ± 6.2 (12–30)             | NA                             |                         |

**Reasons for loss of NEDA during treatment with IFN-β in the 3-year FU with [n of patients]**

- MRI activity: 13 (10)
- Clinical activity: 10 (8)
- Clinical and MRI activity: 9 (2)

Table 1. Demographic, clinical and radiological data for relapsing–remitting MS patients treated with IFN-β in a 3-year follow-up. MS multiple sclerosis, MRI magnetic resonance imaging, IFN-β interferon-β, SD standard deviation, EDSS expanded disability status scale, T2 T2-weigted images, MRI sequence, FLAIR fluid attenuation inversion recovery, MRI sequence, NEDA no evidence of disease activity, Gd gadolinium, FU follow-up, N/A not applicable.
• number of T2/FLAIR lesions at the 1st MRI—a total number of demyelinating plaques assessed on T2-weighted and FLAIR images,
• the presence and number of Gd-enhancing lesions on contrast-enhanced T1-weighted images at the 1st MRI,
• presence of demyelinating lesions in the cervical spine, evaluated on sagittal T2-weighted and contrast-enhanced T1-weighted images at the 1st MRI,
• value of ADC within the thirteen selected areas of NAWM and NAGM (Fig. 2).

In each MS patient the onset and disease duration were determined on the basis of medical records. Baseline disability was evaluated using the EDSS score, by an experienced neurologist.

Radiological parameters were obtained from the 1st MR examinations in MS patients before (MS0 group) or after the first year of treatment (MS1 group) and were assessed by an experienced radiologist, unaware of the clinical data, particularly the presence of future relapses or new lesions in future MR scans.

Image acquisition. MR examinations were performed with a 1.5 T MR scanner (SignaHdx, GE Healthcare) using a 16-channel HNS coil. The conventional MR imaging protocol for MS patients consisted of axial T1-weighted SE, axial T2-weighted FSE, axial FLAIR, sagittal and coronal T2-weighted FRFSE, axial DWI SE/EPI sequence and post-gadolinium T1-weighted 3D-FSPGR images. DWI was performed using an axial single shot, spin-echo type echo-planar images with the following parameters: b = 0 and b = 1,000 mm²/s (TE 89.9 ms, TR 8,000 ms, FOV 26 cm, matrix 128 × 128), thickness: 5 mm, spacing: 0, time of acquisition: 40 s. We used the same method of image acquisition as described in our previously published paper33.

Image analysis and post-processing. Diffusion-weighted imaging data were transferred to a GE Advantage Workstation 4.6. Functool software, provided by the manufacturer, was used in post-processing of images. ADC values were acquired by manually placing regions of interest (ROI), sized approx. 200 mm², using DFOV = 13.0 cm on ADC maps in the following selected normal-appearing white and grey matter regions:

- 1, 2—right and left cerebellar white matter, respectively (Fig. 2a),
- 3—pons (Fig. 2b),
- 4, 5—right and left thalamus, respectively (Fig. 2c),
- 6, 7—right and left head of the caudate nuclei, respectively (Fig. 2d),
- 8, 9—right and left fronto-parietal white matter regions, respectively (Fig. 2e),
- 10, 11—right and left fronto-parietal white matter at the upper slices near convexity, respectively (Fig. 2f),
- 12, 13—right and left temporal white matter of inferior temporal gyri, respectively (Fig. 2g).
T2-weighted images or FLAIR images were utilised to ensure that regions of interest did not include any demyelinating plaques or to exclude partial volume effect from border areas. We decided to choose many regions of interest in an attempt to obtain a more comprehensive insight in a potentially diffused pathology involving NAWM and NAGM. We used the same methods in image analysis and post-processing as we presented in our previously published study.

Statistical analysis. For binary outcomes (model 1), logistic regression was applied. Receiver operating characteristic (ROC) curves were used to choose the most appropriate cut-off value for a test of a binary classifier. In further analysis, the accuracy of the test was measured by the area under the curve (AUC). Sensitivity, specificity, predictive positive value (PPV) and negative predictive value (NPV) of the potential prognostic factors of NEDA loss and its components were calculated (model 1). In model 2 (time to reaching endpoint) Cox regression was used. In model 3 (prediction of reasons for NEDA loss) multinomial logistic regression was applied. The statistical outcomes were expressed by a classical odds ratio (OR), and hazard ratio (HR) together with confidence 95% intervals and p-values.

The false discovery rate correction (Benjamini-Hochberg) was added to adjust p-value. Besides, cross-validation was performed using the Somers’ Dxy rank discrimination index. The computation was conducted in the R statistical platform.

Results

Baseline demographic, clinical and MRI characteristics. Out of a total of 236 patients with a relapsing–remitting course of MS, 87 patients with complete clinical data at baseline and in the 3-year follow-up were included (Fig. 1), with further subdivision into a group of 45 patients with the initial MRI before treatment (MS0 group) and those with the 1st MRI after 1 year of treatment (n = 42, MS1 group). The whole baseline characteristics of both groups are summarised in Table 1. Two patients in the MS0 group and 6 patients in the MS1 group refused contrast administration at the 1st MRI, therefore they were not included in the assessment of presence and number of Gd-enhancing lesions at baseline. The sustaining of NEDA status was analysed until year 3 of observation if sufficient follow-up data was accessible. In the MS0 group, 2 patients were lost-to-follow-up in the 2nd year of observation, because of switching therapy due to first line treatment failure, and 9 patients were excluded from analysis in the 3rd year of follow-up due to treatment change or discontinuation. In the MS1 group, 3 patients were excluded for NEDA assessment between the 1st and 3rd year of treatment because of a lack of the MRI scan after 3 years of treatment and/or resignation of therapy (Table 2).

NEDA at 1-, 2- and 3-year follow-up. In the MS0 group with baseline MRI before treatment at the 1st year of follow-up, 29 of 45 patients (64.4%) sustained NEDA and 16 patients (35.6%) lost NEDA. In detail, 11 patients (24.4%) lost NEDA due to MRI activity as a first finding and 9 patients failed due to clinical activity first. At the two-year follow-up, 43 patients were amenable to assessment, 20 (46.5%) maintained NEDA status, whereas 23 patients (53.5%) lost NEDA, in whom 18 patients (41.9%) did not sustain “MRI” NEDA first and 12 patients (27.9%) lost “clinical” NEDA first. At the end of the 3-year follow-up period, 36 out of the initial 45 patients had appropriate data for analysis. Here, only 12 (33.3%) retained NEDA status, 19 patients (52.8%) presented MRI activity first and 10 patients (27.8%) developed relapses first. In the MS1 group with the 1st MRI after 1 year of treatment NEDA was assessed for periods between the 1st and 2nd and between the 1st and 3rd year of IFN-β treatment, because of a lack of baseline MRI obtained before treatment. Between the 1st and 2nd years of follow-up, 30 patients from 42 (71.4%) maintained NEDA status, 9 patients (21.4%) failed in “MRI” NEDA and 5 patients (11.9%) lost “clinical” NEDA at first. In the period between the 1st and 3rd years of treatment, 39 patients had sufficient clinical and radiological data for evaluation—19 patients (48.7%) retained NEDA status, whereas 23 patients (51.3%) lost NEDA, including 14 patients (35.9%) with “MRI” NEDA loss, 11 patients (28.2%) with “clinical” NEDA loss as a first finding. In both groups and in any period of observation, a majority of patients lost NEDA due to failure in one component, which was mostly associated with formation of new lesions (Table 2).

Best individual prognostic markers of loss of NEDA during treatment with IFN-β. We performed an exploratory multivariate analysis of 24 potentially valuable independent predictors of disease activity according to the NEDA concept in a 1-, 2- and 3-year follow-up.

Model 1—prognostic markers of loss of NEDA and its components. In the MS0 group with baseline MRI before treatment we found only one statistically significant prognostic marker of NEDA loss until the 3rd year of treatment—the ADC value in NAWM of the left cerebellar hemisphere (ROI 2), OR 1.03, p = 0.038. New lesions formation until the 1st year of treatment was predicted by only one factor as well—the ADC value in pons (ROI 3) with OR 1.02, p = 0.026. The most powerful factor in prognosis of loss of “MRI” NEDA was the presence of Gd-enhancing lesion(s) at baseline scan—patients with this feature were almost at a ninefold higher risk of loss of “MRI” NEDA during 2 years of IFN-β treatment.

In the MS1 group with baseline MRI after 1 year of INF-β treatment we found that an increased ADC value in the 1st MRI in the left frontal NAWM (ROI 9), the right and left frontoparietal NAWM (ROI 10 and 11) and in the right temporal NAWM (ROI 12) predicted loss of NEDA between the 1st and 3rd years of treatment with OR 1.02 (p = 0.017–0.047). ADC values obtained from the right and left frontoparietal NAWM (ROI 10 and 11) and from the left temporal NAWM (ROI 13) were significant factors in prognosis of “clinical” NEDA loss between
Table 2. Clinical, radiological and NEDA data of an appropriate period of time in MS patients, according to division into two groups, depending on the time of the 1st MRI as baseline scan. MS multiple sclerosis, NEDA no evidence of disease activity, n number, IFN-β interferon-β, MRI magnetic resonance imaging, N/A not applicable.

|                          | Within the 1st year of treatment | Within the 2nd year of treatment | Within the 3rd year of treatment |
|--------------------------|---------------------------------|---------------------------------|---------------------------------|
| **MS0 group—the 1st MRI before treatment with IFN-β—baseline MRI** |                                 |                                 |                                 |
| Analysed group of patients [n; (% of total baseline)] | 45 (100%) | 43 (95.6%) | 36 (80%) |
| Patients lost-to-follow-up [n; (% of analysed)] | 0 (0%) | 2 (4.4%) | 9 (20%) |
| NEDA maintenance [n; (% of analysed)] | 29 (64.4%) | 20 (46.5%) | 12 (33.3%) |
| Loss of NEDA [n; (% of analysed)] | 16 (35.6%) | 23 (53.5%) | 24 (67.7%) |
| Loss of "MRI" NEDA [n; (% of analysed)] | 11 (24.4%) | 18 (41.9%) | 19 (52.8%) |
| Loss of "clinical” NEDA [n; (% of analysed)] | 9 (19.6%) | 12 (27.9%) | 10 (27.8%) |
| Loss of NEDA due to one component [n; (% of analysed)] | 12 (26.7%) | 16 (37.2%) | 19 (52.8%) |
| Loss of NEDA due to two components [n; (% of analysed)] | 4 (8.9%) | 7 (16.3%) | 5 (13.9%) |
| **MS1 group—the 1st MRI after 1 year of treatment with IFN-β only—on-treatment MRI as baseline** | | | |
| Analysed group of patients [n; (% of total baseline)] | N/A | 42 (100%) | 39 (92.9%) |
| Patients lost-to-follow-up [n; (% of analysed)] | N/A | 0 (0%) | 3 (7.7%) |
| NEDA maintenance [n; (% of analysed)] | N/A | 30 (71.4%) | 19 (48.7%) |
| Loss of NEDA [n; (% of analysed)] | N/A | 12 (28.6%) | 20 (51.3%) |
| Loss of "MRI" NEDA [n; (% of analysed)] | N/A | 9 (21.4%) | 14 (35.9%) |
| Loss of "clinical” NEDA [n; (% of analysed)] | N/A | 5 (11.9%) | 11 (28.2%) |
| Loss of NEDA due to one component [n; (% of analysed)] | N/A | 10 (23.8%) | 15 (38.5%) |
| Loss of NEDA due to two components [n; (% of analysed)] | N/A | 2 (4.8%) | 5 (12.8%) |
cross-validation performance. No other factors increased the risk of reaching the time point of NEDA failure and its components, as well as none of them predicted the time of IFN-β treatment shorter than 3 years or the time to alternative treatment in both groups (Table 5, Suppl. Fig. S3).

**Table 3.** Logistic regression analysis of the association between significant MRI prognostic markers and endpoints related to disease activity (model 1). Presence of the Gd-enhancing lesion at baseline MRI was the strongest predictor of "MRI" NEDA loss in the MS0 group. ADC measurements obtained from the 1st MRI after 1 year of treatment (MS1 group) were most the common significant markers in prognosis of NEDA loss and "clinical" NEDA loss in the subsequent 2 years of IFN-β treatment, with the best performance in a cross-validation procedure, reaching the Somers' Dxy rank discrimination index > 0.6 for the latter endpoints (marked in bold). None of the other baseline demographic or clinical factors increased the risk of NEDA failure and its components in both groups. MS multiple sclerosis, OR odds ratio, CI confidence interval, IFN-β interferon-β, NEDA no evidence of disease activity, ADC apparent diffusion coefficient, ROI region of interest, ADC in ROI 8—right frontal white matter, ADC in ROI 9—left frontal white matter, ADC in ROI 10—right frontoparietal white matter, ADC in ROI 11—left frontoparietal white matter, ADC in ROI 12—right temporal white matter, ADC in ROI 13—left temporal white matter, T2 T2-weighted images, FLAIR fluid attenuation inversion recovery, MRI sequence.
Table 4. Results of ROC analyses for significant prognostic markers of endpoints related to disease activity during IFN-β treatment in a 3 years follow-up and their statistically significant combinations. Single markers achieved higher AUC than their combinations. The best parameters attaining ≥ 80% are marked in bold.

Model 3—prognostic factors of the reasons for NEDA loss. The assessment of reasons for NEDA failure until the end of the 3-year follow-up for all 32 patients with loss of NEDA in the MS0 group showed that NEDA loss resulted from subclinical disease activity in MRI in only 13 patients (40.6% of all patients with NEDA loss), clinical activity in only 10 patients (31.3%), while in 9 patients (28.1%) NEDA failure was a consequence of loss of both components. In the MS1 group a total number of 20 patients experienced NEDA failure, for the following reasons—loss of “MRI” NEDA in 10 patients (50%), loss of “clinical” NEDA in 8 patients (40%) and a combination of both components in 2 patients (10%) (Table 1). None of the 24 analysed potential factors predicted the reason of loss of NEDA in both groups of MS patients.

Benjamini–Hochberg correction. In analysis of the false discovery rate correction, all provided potential predictors remained statistically significant with the adjusted p value < 0.05—data are summarised in Tables 3 and 5.
In the course of cross-validation procedure we found that the best performance with the Somers’ Dxy rank discrimination index was achieved in model 1 in MS1 group in prediction of the “clinical” NEDA loss in both evaluated periods (1st–2nd and 1st–3rd year of IFN-β treatment), reaching moderately high index (Dxy = 0.54–0.63) (Table 3). Apart from that majority of previously described statistically significant prognostic factors were characterised by low to moderate index (Dxy = 0.31–0.49). Details are provided in the last column of Table 3.

### Table 5. Cox regression analysis of the associations between the most crucial demographic, clinical and MRI risk factors of time to loss of NEDA and its components (model 2). In the MS0 group the presence of the Gd-enhancing lesion at baseline MRI increased almost 3-times the risk of reaching loss of NEDA and almost 5-times the risk of reaching loss of “MRI” NEDA. In the MS1 group ADC values in supratentorial areas obtained at MRI after 1 year of treatment increased the risk of loss of NEDA and its clinical component by about 1%

**Cross-validation procedure.** In the course of cross-validation procedure we found that the best performance with the Somers’ Dxy rank discrimination index was achieved in model 1 in MS1 group in prediction of the “clinical” NEDA loss in both evaluated periods (1st–2nd and 1st–3rd year of IFN-β treatment), reaching moderately high index (Dxy = 0.54–0.63) (Table 3). Apart from that majority of previously described statistically significant prognostic factors were characterised by low to moderate index (Dxy = 0.31–0.49). Details are provided in the last column of Table 3 and 5.

**Discussion**

The prompt identification of MS patients with insufficient response to disease-modifying treatment is pivotal for selecting candidates to change the therapy, aiming at an individualised treatment strategy for optimal control of the disease. The fundamental challenge in the evaluation of potential predictors is the lack of a shared definition of treatment response in MS. Non-response to treatment is usually assessed on the basis of one of three outcomes or their combination: disability progression, occurrence of relapses, and/or presence of new/active MRI lesions. However, in the literature variable criteria based on these responses have been used within different follow-up procedures. NEDA is a concept introduced in clinical trials of natalizumab in 2009 by Havrdova et al., as a surrogate for treatment response based on no evidence of disease activity neither clinical
(relapses, worsening disability) nor subclinical (new MRI lesions)\textsuperscript{22}. Nowadays, some modifications to the primary definitions have been made, with addition of the fourth and fifth domain—pathological volume loss of the brain and raised cerebrospinal fluid neurofilament level, respectively\textsuperscript{23}. NEDA is increasingly used in real-world datasets\textsuperscript{23}, nevertheless there are some flaws in using NEDA as a goal of treatment—the main drawback is that each NEDA component is equal. As a consequence, a new clinically silent lesion in MRI is as important as the occurrence of a severely disabling relapse\textsuperscript{24}.

In our study we applied NEDA criteria retrospectively in the RMS cohort treated with IFN-β as a first-line therapy. We demonstrated NEDA rates of 64.4%, 46.5% and 33.3% after the 1st, 2nd and 3rd year of treatment, respectively in patients with the initial MRI before therapy, as well as 71.4% and 48.7% for periods 1st–2nd and 1st–3rd years of treatment, respectively, with the 1st MRI after 1 year of treatment (Table 2). Higher rates of NEDA maintenance in the second group (MS1) may result from underestimation of the first year of therapy, when it was not amenable to assess the formation of new lesions, due to a lack of MRI data. Besides, we received higher rates of NEDA maintenance in both groups compared to the study of Huhn et al., where rates of 45%, 29%, and 21% were achieved at each analogical year of treatment\textsuperscript{25} compared with our MS0 group. Apart from a known individual variability in the course of MS, these differences may result from distinctive inclusion criteria—we analysed patients treated with IFN-β only, whereas in the cited study patients treated with various drugs were included\textsuperscript{25}.

Commonly reported predictors or prognostic factors of treatment response include age\textsuperscript{5}, sex, disease duration\textsuperscript{6,8}, baseline disability\textsuperscript{8,9}, number of relapses during the first year of treatment\textsuperscript{9}, presence and/or number and/or volume of new lesions on T2-weighted images or gadolinium-enhancing lesions\textsuperscript{9,14}. In our cohort we found a few relations between some of these factors and risk of NEDA loss. In the MS0 group the presence of Gd-enhancing lesion(s) at baseline scan was the best predictor of “MRI” NEDA loss until the 2nd year of therapy (OR 8.94), time to NEDA loss (HR 2.9) and time to “MRI” NEDA loss (HR 4.77). Apart from that, baseline EDSS predicted time to loss of “clinical” NEDA with a 1.37 hazard ratio. However, all of them reached slight to low validation index (Dxy 0.17–0.36). In the MS1 group, the number of T2/FLAIR lesions at the 1st MRI favoured loss of “clinical” NEDA between the 1st and 3rd years of therapy (OR 1.11, Dxy 0.55) and increased the risk of time to loss of “clinical” NEDA (HR 1.06, Dxy 0.38) (Tables 3 and 5).

As there is a scarcity of data regarding the use of DWI measurements in the prognosis of IFN-β treatment response\textsuperscript{16}, we decided to evaluate the usefulness of easily accessible ADC measurements in this role. Involvement of so-called normal-appearing white and grey matter by a pathological process even in early diagnosed MS patients has been commonly investigated\textsuperscript{16,27,37,38} and a connection with that detected by advanced MRI techniques facilitated diffusion was made\textsuperscript{27}. This observation is mainly explained by three phenomena in the literature: firstly, conventional MRI sequences used at 1.5 T or 3 T may be deficient in demonstrating all demyelinated lesions in both white and grey matter—the use of higher field strength devices enables the detection of more plaques in regions supposed to be normal on conventional MRI\textsuperscript{37}. Secondly, diffusion derangements can predate the formation of new demyelinating plaques\textsuperscript{37}. Thirdly, even though MS is regarded as a primarily demyelinating disease, the axonopathy occurs parallel beyond the plaques even at the early stage of the disease\textsuperscript{8,9,38} which may be related to Wallerian degeneration, in which axons traversing focal lesions are damaged even at a far distance from the demyelinating plaque\textsuperscript{40,41}. Retrogenesis is the other hypothesis, assuming that late-myelinating fibres are more prone to age-related and disease-related degeneration and consequently, they are more likely to show diffusion alterations first\textsuperscript{42}.

According to our analysis, ADC measurements in some regions are connected with a statistically significant higher risk of loss of NEDA and its components. In a group of patients with baseline MRI before treatment, we found that ADC measured in infratentorial white matter regions (ROIs 1–3, cerebellum and pons) predicted loss of NEDA, loss of “MRI” NEDA (model 1) and time to “MRI” NEDA loss (model 2), but with slight to moderate validation coefficient (Dxy 0.18–0.47). Conversely, in patients with the 1st MRI after 1 year of treatment, supratentorial ADC measurements (ROIs 8–13—frontal, frontoparietal and temporal NAWM) escalated the risk of NEDA loss between the 1st and 3rd year of treatment and “clinical” NEDA loss between the 1st and 2nd, reaching the highest accuracy ≥ 80% and the highest performance in cross-validation (Dxy 0.61–0.63) among investigated factors. ADC measurements in these locations predicted also the “clinical” NEDA failure between the 1st and 3rd year of treatment with a little lower accuracy of 77.0–81.4% and validation coefficient (Dxy 0.54–0.63). In model 2, time to loss of NEDA and its “clinical” component was predicted by ADC obtained from the supratentorial NAWM regions as well. Each ADC value in both groups was associated with an increase in appropriate risk (OR or HR) between 1–3% (Tables 3 and 5), which was far lower than the increase of some clinical and conventional MRI factors (e.g. the presence of a Gd-enhancing lesion), but, important to note, an increase in just one step of ADC value (e.g. from 779 to 780 × 10\textsuperscript{−6} mm\textsuperscript{2}/s) implicated escalation of a risk in 1–3%. Apart from that most other investigated factors were not useable in predicting any of the seventeen proposed outcomes, whereas ADC measurements did.

There are some limitations of our study. Firstly, the study sample is small—we could include only 87 from all 236 patients managed at our institution because of the tight inclusion criteria. Secondly, we had only 45 patients with true baseline MRI before treatment, however we found that ADC measurements in on-treatment MRI are even more commonly and in better degree associated with statistically significant prediction of subsequent loss of NEDA, particularly the loss of “clinical” NEDA. Thirdly, ADC measurements cannot be applied to all MS patients—patients with numerous plaques and plaques in regions of interest are not amenable to this method. On the other hand, we provided some novelty by using ADC measurements in the prognosis of disease activity during IFN-β treatment as a simple and easy tool.
Conclusions

In conclusion, our results seem to suggest that the ADC measurements of NAWM, particularly in the frontal, frontoparietal and temporal regions obtained after 1 year of treatment, may contribute to the prognosis of MS activity according to the NEDA concept during interferon-β therapy. This is a relatively easy imaging measure, that might be incorporated into standard follow-up procedures in MS patients. However, further research of this method should be performed before its widespread implementation.

Data availability

Data will be available on demand, there is no data related to this article in data repositories.

Received: 6 October 2019; Accepted: 3 July 2020
Published online: 30 July 2020

References

1. Filippi, M. et al. Multiple sclerosis. *Nat. Rev. Dis. Prim.* 8, 43 (2018).
2. Gasserini, C. et al. Unraveling treatment response in multiple sclerosis: a clinical and MRI challenge. *Neurology* 92, 180–192 (2019).
3. Bergamaschi, R. et al. Immunomodulatory therapies delay disease progression in multiple sclerosis. *Mult. Scler. J.* 22, 1732–1740 (2012).
4. Río, J. & Ruiz-Peña, J. L. Short-term suboptimal response criteria for predicting long-term non-response to first-line disease modifying therapies in multiple sclerosis: a systematic review and meta-analysis. *J. Neurol. Sci.* 361, 158–167 (2016).
5. Cierny, D. et al. The age at onset in Multiple Sclerosis is associated with patient’s prognosis. *Brattis Med J* 118, 374–377 (2017).
6. Healy, B. C. et al. Long-term follow-up for multiple sclerosis patients initially treated with interferon-beta and glatiramer acetate. *J. Neurol. Sci.* 394, 127–131 (2018).
7. Cavallari, M. et al. Fatigue predicts disease worsening in relapsing-remitting multiple sclerosis patients. *Mult. Scler. J.* 22, 1841–1849 (2016).
8. Uher, T. et al. Combining clinical and magnetic resonance imaging markers enhances prediction of 12-year disability in multiple sclerosis. *Mult. Scler. J.* 23, 51–61 (2017).
9. Galassi, S. et al. A lesion topography-based approach to predict the outcomes of patients with multiple sclerosis treated with interferon beta. *Mult. Scler. Relat. Disord.* 8, 99–106 (2016).
10. Río, J. et al. Disability progression markers over 6–12 years in interferon-β-treated multiple sclerosis patients. *Mult. Scler. J.* 24, 322–330 (2017).
11. Durelli, L. et al. MRI activity and neutralising antibody as predictors of response to interferon β treatment in multiple sclerosis. *J. Neurol. Neurosurg. Psychiatry* 79, 646–651 (2008).
12. Horakova, D. et al. Early predictors of non-response to interferon in multiple sclerosis. *Acta Neurol. Scand.* 126, 390–397 (2012).
13. Prosperini, L., Gallo, V., Petsas, N., Borriello, G. & Pozzilli, C. One-year MRI scan predicts clinical response to interferon beta in multiple sclerosis. *Eur. J. Neurol.* 16, 1202–1209 (2009).
14. Pérez-Miralles, F. C. et al. Predictive value of early brain atrophy on response in patients treated with interferon β. *Neuroimmunol. Neuroinflammation* 2, 1 (2015).
15. Enzinger, C. et al. Nonconventional MRI and microstructural cerebral changes in multiple sclerosis. *Nat. Rev. Neurol.* 11, 676–686 (2015).
16. Fiore, M. et al. Diffusion tensor imaging and disability progression in multiple sclerosis: a 4-year follow-up study. *Brain Behav.* 9, 1–10 (2019).
17. Rötstein, D. & Montalban, X. Reaching an evidence-based prognosis for personalized treatment of multiple sclerosis. *Nat. Rev. Neurol.* 15, 287–300 (2019).
18. Río, J. et al. Measures in the first year of therapy predict the response to interferon β in MS. *Mult. Scler.* 15, 848–853 (2009).
19. Sormani, M. et al. Scoring treatment response in patients with relapsing multiple sclerosis. *Mult. Scler. J.* 19, 605–612 (2012).
20. Sormani, M. P. et al. Assessing response to interferon-β in a multicenter dataset of patients with MS. *Neurology* 87, 134–140 (2016).
21. Tür, C. et al. Assessing treatment outcomes in multiple sclerosis trials and in the clinical setting. *Nat. Rev. Neurol.* 14, 75–93 (2018).
22. Hafvadsson, E. et al. Effect of Natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab safety and efficacy in relapsing-remitting Multiple Sclerosis (AFFIRM) study. *Lancet Neurol.* 8, 254–260 (2009).
23. Huhn, K. et al. No evidence of disease activity status over 3 years in a real-world cohort of relapsing remitting MS patients in Germany. *Mult. Scler. Relat. Disord.* 27, 133–138 (2019).
24. Giovannoni, G., Birmel, R., Phillips, T. & Rudick, R. A brief history of NEDA. *Mult. Scler.* 25, 1157–1167 (2019).
25. Hafvadsson, E. et al. Natalizumab safety and efficacy in relapsing-remitting multiple sclerosis (AFFIRM) study. *Brain Behav.* 51–61 (2017).
26. Kolinski, J. et al. A combined post-mortem magnetic resonance imaging and quantitative histological study of multiple sclerosis pathology. *Brain* 135, 2938–2951 (2012).
27. Sormani, M. P. Prognostic factors versus markers of response to treatment versus surrogate endpoints: three different concepts. *Mult. Scler. J.* 23, 378–381 (2017).
28. Polman, C. H. et al. Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria. *Ann. Neurol.* 69, 292–302 (2011).
29. Thompson, A. J. et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. *Lancet Neurol.* 17, 1 (2017).
30. Filippi, M. & Rocca, M. A. MRI evidence for multiple sclerosis as a diffuse disease of the central nervous system. *J. Neurol.* 252, 16–24 (2005).
39. Ceccarelli, A. *et al.* Normal-appearing white and grey matter damage in MS: a volumetric and diffusion tensor MRI study at 3.0 Tesla. *J. Neurol.* **254**, 513–518 (2007).
40. Dziedzic, T. *et al.* Wallerian degeneration: a major component of early axonal pathology in multiple sclerosis. *Brain Pathol.* **20**, 976–985 (2010).
41. Ciccarelli, O. *et al.* A study of the mechanisms of normal-appearing white matter damage in multiple sclerosis using diffusion tensor imaging: evidence of Wallerian degeneration. *J. Neurol.* **250**, 287–292 (2003).
42. Benitez, A. *et al.* White matter tract integrity metrics reflect the vulnerability of late-myelinating tracts in Alzheimer’s disease. *NeuroImage Clin.* **4**, 64–71 (2014).

**Acknowledgements**

We would like to acknowledge Prof. A. Tukiendorf for statistical analysis.

**Author contributions**

A.Z.G., J.B., A.P.D.: substantial contributions to the conception. A.Z.G., J.B.: design of the work. A.Z.G., J.B.: the acquisition, analysis. A.Z.G., J.B.: interpretation of data. A.Z.G.: draft of the work. J.B., M.S., S.B., G.T., A.P.D.: substantial revision. All of authors have approved the submitted version (and any substantially modified version that involves the author’s contribution to the study) and have agreed both to be personally accountable for the author’s own contributions and to ensure that questions related to the accuracy or integrity of any part of the work, even ones in which the author was not personally involved, are appropriately investigated, resolved, and the resolution documented in the literature.

**Competing interests**

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors. This research was carried out using information collected during normal patient care, and extra time was spent for data analysis and interpretation. The authors declares no competing interests.

**Additional information**

Supplementary information is available for this paper at [https://doi.org/10.1038/s41598-020-69383-3](https://doi.org/10.1038/s41598-020-69383-3).

**Correspondence** and requests for materials should be addressed to A.Z.-G.

**Reprints and permissions information** is available at [www.nature.com/reprints](http://www.nature.com/reprints).

**Publisher’s note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

---

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit [http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/).

© The Author(s) 2020